Real-world data sheds light on breast cancer treatment in seniors
NCT ID NCT06086340
First seen Nov 18, 2025 · Last updated May 16, 2026 · Updated 20 times
Summary
This study analyzed medical records from 779 Medicare patients aged 65 and older with a specific type of advanced breast cancer (HR+/HER2-). It compared survival between those who received a combination of palbociclib and an aromatase inhibitor (AI) versus those who received an AI alone. The goal was to see if the combination therapy improved overall survival in a real-world setting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer New York
New York, New York, 10001, United States
Conditions
Explore the condition pages connected to this study.